Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that its Phase 1b study GLP-1-H24-4 successfully achieved its primary endpoint, demonstrating that DehydraTECH-semaglutide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE